20 results found.

Neoplasms, Pancreas Clinical Trial using cancer stem cell vaccine

Fuda Cancer Hospital, Guangzhou - Recruiting 18 years to 75 years.
- Study of Cancer Stem Cell Vaccine That as a Specific Antigen in Metastatic Adenocarcinoma of the Pancreas.
cancer stem cell vaccine

Metastatic Pancreatic Adenocarcinoma Clinical Trial using Ipilimumab; Vaccine; FOLFIRINOX

Sidney Kimmel Comprehensive Cancer Center - Recruiting 18 years or older.
- A Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab in Combination With Allogeneic GM-CSF Transfected Pancreatic Tumor Vaccine (GVAX) in the Treatment of Metastatic Pancreatic Cancer.
Ipilimumab; Vaccine; FOLFIRINOX

Metastatic Pancreatic Adenocarcinoma Clinical Trial using PEGPH20; Oxaliplatin; Leucovorin; Irinotecan; 5-fluorouracil

Southwest Oncology Group - Recruiting 18 years or older.
- S1313, A Phase IB/II Randomized Study of Modified FOLFIRINOX + Pegylated Recombinant Human Hyaluronidase (PEGPH20) Versus Modified FOLFIRINOX Alone in Patients With Good Performance Status Metastatic Pancreatic Adenocarcinoma.
PEGPH20; Oxaliplatin; Leucovorin; Irinotecan; 5-fluorouracil

Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcin Clinical Trial using vismodegib; sirolimus; positron emission tomography; computed tomography; pharmacological study; laboratory biomarker analysis; fludeoxyglucose F 18

Mayo Clinic - Recruiting 18 years or older.
- Phase I Trial of The Combination of Vismodegib and Sirolimus.
vismodegib; sirolimus; positron emission tomography; computed tomography; pharmacological study; laboratory biomarker analysis; fludeoxyglucose F 18

2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer Clinical Trial using GVAX Pancreas Vaccine; CRS-207; gemcitabine, capecitabine, 5-FU, irinotecan or erlotinib; cyclophosphamide

Aduro BioTech, Inc. - Recruiting 18 years or older.
- A Phase 2B, Randomized, Controlled, Multicenter, Open-Label Study of the Efficacy and Immune Response of GVAX Pancreas Vaccine (With Cyclophosphamide) and CRS 207 Compared to Chemotherapy or to CRS-207 Alone in Adults With Previously-Treated Metastatic Pancreatic Adenocarcinoma.
GVAX Pancreas Vaccine; CRS-207; gemcitabine, capecitabine, 5-FU, irinotecan or erlotinib; cyclophosphamide

Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcin Clinical Trial using gemcitabine hydrochloride; dasatinib; erlotinib hydrochloride

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1 Study of Gemcitabine, Dasatinib and Erlotinib in Patients With Advanced Pancreatic Carcinoma.
gemcitabine hydrochloride; dasatinib; erlotinib hydrochloride

KRAS Mutated Colorectal Adenocarcinoma, Metastatic Pancreatic Ade Clinical Trial using MEK162 + AMG 479

Novartis - Recruiting 18 years or older.
- A Phase Ib/II Open-label, Multi-center Study of the Combination of MEK162 Plus AMG 479 (Ganitumab) in Adult Patients With Selected Advanced Solid Tumors.
MEK162 + AMG 479

Pancreatic Cancer Clinical Trial using TH-302; Nab-paclitaxel; Gemcitabine

EMD Serono - Recruiting 18 years or older.
- An Open-Label, Phase I Dose Escalation Trial of TH-302 in Combination With Gemcitabine and Nab-Paclitaxel in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma.
TH-302; Nab-paclitaxel; Gemcitabine

Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcin Clinical Trial using 6,8-bis(benzylthio)octanoic acid; oxaliplatin; leucovorin calcium; irinotecan hydrochloride; fluorouracil; laboratory biomarker analysis

Comprehensive Cancer Center of Wake Forest University - Recruiting 18 years or older.
- A Phase I Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer and Good Performance Status.
6,8-bis(benzylthio)octanoic acid; oxaliplatin; leucovorin calcium; irinotecan hydrochloride; fluorouracil; laboratory biomarker analysis

Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcin Clinical Trial using 6,8-bis(benzylthio)octanoic acid

Comprehensive Cancer Center of Wake Forest University - Recruiting 18 years or older.
- A Pilot Study: Open-Label Clinical Trial of CPI-613 in Patients With Metastatic Pancreatic Adenocarcinoma and Poor Performance Status.
6,8-bis(benzylthio)octanoic acid

Pancreatic Cancer, or Colorectal Cancer Clinical Trial using Cancer macrobead placement in abdominal cavity

The Rogosin Institute - Recruiting 18 years or older.
- An Open-Label Phase 2 Efficacy Trial of the Implantation of Mouse Renal Adenocarcinoma Cell-Containing Agarose-Agarose Macrobeads in the Treatment of Patients With Treatment-Resistant, Metastatic Pancreatic or Colorectal Adenocarcinoma.
Cancer macrobead placement in abdominal cavity

Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, or S Clinical Trial using wild-type reovirus; carboplatin; paclitaxel

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A 2-arm Randomized Phase II Study of Carboplatin, Paclitaxel Plus Reovirus Serotype-3 Dearing Strain (Reolysinr) vs. Carboplatin and Paclitaxel in the First Line Treatment of Patients With Recurrent or Metastatic Pancreatic Cancer.
wild-type reovirus; carboplatin; paclitaxel

Metastatic Pancreatic Cancer, or Pancreatic Cancer Clinical Trial using IMMU-107; placebo; Gemcitabine

Immunomedics, Inc. - Recruiting 18 years or older.
- An International, Multi-Center, Double-Blind, Randomized, Phase III Trial of 90Y-Clivatuzumab Tetraxetan Plus Low-Dose Gemcitabine Versus Placebo Plus Low-Dose Gemcitabine in Patients With Metastatic (Stage IV) Pancreatic Adenocarcinoma Who Received at Least Two Prior Treatments (PANCRIT-1).
IMMU-107; placebo; Gemcitabine

Pancreatic Cancer Metastatic Clinical Trial using Dasatinib; mFOLFOX6

University of Florida - Recruiting 18 years or older.
- Phase II Study of 5-Fluorouracil, Oxaliplatin Plus Dasatinib (FOLFOX-D) in First-line Metastatic Pancreatic Adenocarcinoma.
Dasatinib; mFOLFOX6

Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcin Clinical Trial using dinaciclib; Akt inhibitor MK2206; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I Trial of Dinaciclib (SCH727965) and MK-2206 in Metastatic Pancreatic Cancer With an Expansion Cohort in Advanced Pancreatic Cancer.
dinaciclib; Akt inhibitor MK2206; pharmacological study; laboratory biomarker analysis

Solid Tumors, Untreated Pancreatic Adenocarcinoma, Pancreatic Can Clinical Trial using PLX7486-TsOH; gemcitabine; nab-Paclitaxel

Plexxikon - Recruiting 18 years or older.
- A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX7486 as a Single Agent and in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced Solid Tumors.
PLX7486-TsOH; gemcitabine; nab-Paclitaxel

Breast Cancer, Pancreatic Cancer, Colorectal Cancer, Non-small-ce Clinical Trial using MORAb-066

Morphotek - Recruiting 18 years or older.
- A Phase I Study of the Safety, Tolerability, and PK of MORAb-066, a Humanized Monoclonal Antibody to Human TF, in Patients With Advanced or Metastatic Breast, Pancreatic, Colorectal, or NSCLC (Adenocarcinoma) Malignancies.
MORAb-066

Stage IV Pancreatic Cancer Clinical Trial using nab-paclitaxel; Cisplatin; gemcitabine

Pancreatic Cancer Research Team - Recruiting 18 years or older.
- A Phase 1b/2 Pilot Trial of Nab-Paclitaxel Plus Cisplatin Plus Gemcitabine (Nabplagem) in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PDA).
nab-paclitaxel; Cisplatin; gemcitabine

Metastatic Pancreatic Adenocarcinoma Clinical Trial using Gemcitabine; Erlotinib; Oxaliplatin; Folinic Acid; Irinotecan; 5-FU

Ludwig-Maximilians - University of Munich - Recruiting 18 years to 75 years.
- Phase II Study to Evaluatate the Efficacy of Gemcitabine Plus Erlotinib for RASH-positive Patients With Metastatic Pancreatic Cancer and Friendly Risk Circumstances.
Gemcitabine; Erlotinib; Oxaliplatin; Folinic Acid; Irinotecan; 5-FU

Adenocarcinoma of the Pancreas, or Metastatic Disease Clinical Trial using AUY922

University Health Network, Toronto - Recruiting 18 years or older.
- A Phase II Single Arm Study of AUY922 in Patients With Metastatic Pancreatic Adenocarcinoma Who Are Resistant to First Line Chemotherapy.
AUY922